Media & Technology
Selling PPE to Government Agencies; the Rise of GTX Corp (GTXO)
GTX Corp (GTXO) is making a big move up the charts in recent days on a massive surge of volume hitting highs of $0.15. The stock has quickly attracted legions of new shareholders and is emerging as a volume leader averaging over $3 million in dollar volume per day. Microcapdaily first reported on GTXO in February of last year when the stock was a little over $0.01.
GTX recently launched COVID Antibody test kits and has noticed a significant increase in demand. Available at wholesale volume pricing and direct to consumers on GTX’s website which is currently selling 2 Rapid Test kits for $34.99 with free shipping. The Rapid Test Kit detects antibodies to SARS-CoV-2 with 97% accuracy in less than 15 minutes, and provides an affordable and convenient home/office testing solution for individuals who want to know if they have been previously infected with the virus or before and after receiving a vaccine to monitor their levels of antibodies. The Company said it has fulfilled multiple orders for PPE from government agencies including the United States Marine Corps, the U.S. Navy, the U.S. Department of Agriculture, and the U.S. Department of Veterans Affairs. These orders were quickly processed and shipped in coordination with our strategic partner, Kiernan Group Holdings (KGH), a risk management firm headquartered in Alexandria, VA.
GTX Corp (GTXO) is a pioneer in smart, mobile and wearable GPS tracking and recovery location based products, supported through a proprietary IoT enterprise monitoring platform. GTX offers a global end-to-end solution of hardware, software and connectivity. GTX Corp develops 2 way GPS tracking technologies which seamlessly integrate with consumer products and enterprise applications. GTX Corp utilizes the latest in miniaturized, low power consumption GPS, Cellular, RF, BLE and NFC technology enabling subscribers to track in real time the whereabouts of people or high value assets through a complete end to end – customizable transceiver module, wireless connectivity gateway, smart phone Apps, middleware, and IoT portal. Headquartered in Los Angeles, California, GTX is known for its award-winning patented GPS SmartSole® – Think Dr. Scholl’s meets LoJack, the world’s first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism and traumatic brain injury. GTX Corp’s business model is built around technology innovation and holds over 85 patents with many issued patents in the area of GPS tracking. The company has international distributors servicing customers in over 35 countries and is a U.S. Military Government contractor. Other customers include public health agencies and municipalities, emergency and police authorities, private companies, public and private senior care homes, and consumers.
GTXO has international distributors servicing customers in over 35 countries and is a U.S. Military Government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers. The Company is most widely known for its patented GPS SmartSole and Smartphone GPS Tracking App. GTXO also owns and licenses a large portfolio of patents in the GPS and wearable technology space, has several consumer products available on its online store and Amazon and most recently soft launched its new NFC Veritap solution.
In November GTXO reported financial results for the Third Quarter ended September 30, 2020. Management stated: “For the third quarter 2020, we saw a 7% increase in revenues and showed a net profit of slightly over $33k. By expanding our Health & Safety business we maintained our cash flow, broadened the visibility of our brand in the market, garnered a lot of new customers, and supported the national effort to keep people safe by providing high quality, FDA approved and many “Made in the U.S.A.” medical protective supplies.
We are seeing a lot of demand for our flagship GPS SmartSole product and began testing our new 4G prototypes during this quarter. We found some issues with our first design, which were quickly resolved and now we have a second version of prototypes in production, which we expect to start testing in the coming weeks. We are also seeing some increase in activity in our IP licensing as the economy reopens. During the third quarter, we finalized hardware development of our next generation miniaturized GPS tracking device, which will utilize a host of new technologies, including CatM1, NB-IoT, Assisted GPS for better accuracy, faster location requests and less power consumption. The Company was also issued a patent by the United States Patent and Trademark Office (USPTO), U.S Patent No. 10,743,615 entitled “System and Method for Embedding A Tracking Device in a Footwear Insole.” This is GTX’s third patent related to embedding Real-Time Location Systems (RTLS) GPS wearable tracking technology into footwear.
GTX Corp’s updated, full-line of PPE can be found on its dedicated website www.gtxmask.com (use promocode ‘open4biz’ and get a discount on your first order) We also just received our first shipment of Antibody tests and plan to announce distribution details shortly.
To Find out the inside Scoop on GTXO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
GTX recently launched COVID Antibody test kits and has noticed a significant increase in demand. Available at wholesale volume pricing and direct to consumers on GTX’s website which is currently selling 2 Rapid Test kits for $34.99 with free shipping. The Rapid Test Kit detects antibodies to SARS-CoV-2 with 97% accuracy in less than 15 minutes, and provides an affordable and convenient home/office testing solution for individuals who want to know if they have been previously infected with the virus or before and after receiving a vaccine to monitor their levels of antibodies.
GTXO reported it has fulfilled multiple orders for PPE from government agencies including the United States Marine Corps, the U.S. Navy, the U.S. Department of Agriculture, and the U.S. Department of Veterans Affairs. These orders were quickly processed and shipped in coordination with our strategic partner, Kiernan Group Holdings (KGH), a risk management firm headquartered in Alexandria, VA.
The Company has signed a collaboration agreement with Pawtocol, a Miami based global online community for the pet industry. Under the agreement GTX will explore integrating IoT sensors and embedded tech to collect and share pet data, leveraging Pawtocol’s blockchain technology. GTX’s Rover Tracker, which is a GPS and NFC IoT device designed for the rapid recovery and profile identification of pets, will be the first device tested on the platform.
Patrick Bertagna, CEO of GTX Corp stated: “As the pandemic shows no signs of slowing down, now more than ever there is a growing need for just in time delivery of crucially needed protective equipment and COVID-19 IgG/IgM Antibody Rapid Test Kits. In partnership with KGH, we have expanded our ability to support government agencies and gained visibility into additional market sectors, while empowering KGH to provide a wide range of health and safety products to the community.”
https://twitter.com/S_AnglinIV/status/1351596763296231424
For More on GTXO Subscribe Right Now!
GTXO is making a big move up the charts in recent days on a massive surge of volume hitting highs of $0.15. The stock has quickly attracted legions of new shareholders and is emerging as a volume leader averaging over $3 million in dollar volume per day. Microcapdaily first reported on GTXO in February of last year when the stock was a little over $0.01. GTX recently launched COVID Antibody test kits and has noticed a significant increase in demand. Available at wholesale volume pricing and direct to consumers on GTX’s website which is currently selling 2 Rapid Test kits for $34.99 with free shipping. The Rapid Test Kit detects antibodies to SARS-CoV-2 with 97% accuracy in less than 15 minutes, and provides an affordable and convenient home/office testing solution for individuals who want to know if they have been previously infected with the virus or before and after receiving a vaccine to monitor their levels of antibodies. The Company said it has fulfilled multiple orders for PPE from government agencies including the United States Marine Corps, the U.S. Navy, the U.S. Department of Agriculture, and the U.S. Department of Veterans Affairs. These orders were quickly processed and shipped in coordination with our strategic partner, Kiernan Group Holdings (KGH), a risk management firm headquartered in Alexandria, VA. In November GTXO reported financial results for the Third Quarter ended September 30, 2020. Management stated: “For the third quarter 2020, we saw a 7% increase in revenues and showed a net profit of slightly over $33k. By expanding our Health & Safety business we maintained our cash flow, broadened the visibility of our brand in the market, garnered a lot of new customers, and supported the national effort to keep people safe by providing high quality, FDA approved and many “Made in the U.S.A.” medical protective supplies. We will be updating on GTXI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GTXO.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in GTXO either long or short and we have not been compensated for this article
LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.
GAMMABODY™ PLATFORM
LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.
To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.
In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.
My big % winning day trade today was $LVTX.
All I did was follow the system.
It has a small float.
Fresh meet never pumped before.
Big News out.
Giant volume.
Why I jumped in early and took profits on the spike in volume. pic.twitter.com/2knPeC5RHz— Trader Brian Jones (@MasterBJones) June 2, 2023
As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates.
The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.
$LVTX $66mil mcap, $133mil in cash at the end of December, cash runway into 2026, median price target $13 (443% upside)
— Jake Weber (@BioStockAnalyst) June 2, 2023
Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.
Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.
$LVTX has three gamma-delta t cell drug candidates in early-stage trials, including collaboration with $SGEN for solid tumors.
— Jake Weber (@BioStockAnalyst) June 2, 2023
In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.
We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.
Revolutionizing User Experience and Driving Stock Surge
$onfo in news and float are lit pic.twitter.com/7afKMOfdz2
— …frankyboyz… (@frankyboyz77) May 26, 2023
With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.
To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ONFO just took the elevator to the top!
Now just waiting on $CYTO pic.twitter.com/OfJgNb1ty0
— 💎 DBR 💎 (@dbr_land) May 26, 2023
Evaluating Financial Performance
While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.
*says the word "AI" once
* $ONFO +76% at market open pic.twitter.com/gOLBZjlqJ2
— Commonstock (@JoinCommonstock) May 26, 2023
Investment Outlook and Future Prospects
Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.
$onfo in news and float are lit pic.twitter.com/Q8eIveRfgd
— …frankyboyz… (@frankyboyz77) May 26, 2023
About MightyDeals.com
Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.
About Onfolio Holdings Inc.
Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.
$ONFO #Ai have you seen this stock? Just came out with a competitive AI software that will fight against the tech kings #microsoft #google
— Don’t Look Down (@M_1Ball) May 26, 2023
Conclusion
Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.
$ONFO – "AI program" is laughable. Check it out on https://t.co/0LdCQCWC28. I searched for "shoes" and flower bouquets showed up. I put in a search for "dogs" and african animals came up.
Plus, lockup expiry is tomorrow, so this is a blatant pump and dump: pic.twitter.com/QnYVoDnqqr
— Adam Gefvert, CFA (@Shiningboy) May 26, 2023
We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.
The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.
To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ENVB halted up
— Antonio Costa (@ACInvestorBlog) May 18, 2023
Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.
$ENVB 💰💰💰💰💰 pic.twitter.com/qCIxiCpF0E
— FonsieTrader (@FonsieTrader) May 18, 2023
Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.
$ENVB 👇this is an important milestone for the company! The price could increase fivefold wit the time imo.
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
— Swingy John (@daytrader_2020) May 18, 2023
We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gino Crescoli from Pixabay
Farmer Brothers (NASDAQ:FARM) Announces $100 Million Sale of Northlake Facility, Shifts Production with Focus on Profitability
Hoth Therapeutics (NASDAQ: HOTH) Makes Groundbreaking Progress in Alzheimer’s Research through HT-ALZ Therapy
Strong Financials and Social Media Buzz Propel Forza X1, Inc. (NASDAQ:FRZA) to New Heights
LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum
Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions
-
Uncategorized6 months agoMeta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider2 years agoMedium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology2 years agoHealthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology3 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years agoSNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma1 year agoAsia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized7 months agoMeta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma2 years agoHumbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange
DEE
January 26, 2021 at 6:46 pm
Great article. You cover many runners so its great to see you noticed this one today!